Table 2

Patient characteristics at the time of the second ADD initiation, by drug class added in subcohort 1|| (N = 357,482)

GLP-1RASGLT2iINSTZDDPP-4iSUOther§All
n1 (% of N)15,448 (4)5,971 (2)49,939 (14)33,021 (9)61,508 (17)187,819 (53)3,776 (1)357,482 (100)
Time from first to second ADD (months)*11.1 (18.58)18.52 (23.73)5.74 (14.58)4.09 (11.19)11.15 (18.95)7.38 (16.08)7.35 (15.92)7.84 (16.5)
Follow-up from second ADD initiation (years)*2.97 (2.44)0.95 (0.66)2.71 (2.26)4.77 (2.98)2.68 (2.01)3.34 (2.56)3.59 (2.65)3.22 (2.53)
Follow-up ≥1 year from second ADD initiation, n2 (% of n1)11,431 (74)2,558 (43)36,337 (73)28,841 (87)46,822 (76)149,109 (79)3,090 (82)278,188 (78)
Discontinuation within 1 year, n (% of n2)2,407 (21)643 (25)2,537 (7)5,913 (21)8,234 (18)15,569 (10)724 (23)36,027 (13)
Age (years)*53 (12)54 (11)57 (13)58 (11)58 (12)60 (12)61 (12)59 (12)
Age ≥70 years, n (% of n1)1,203 (8)435 (7)9,576 (19)6,450 (20)11,595 (19)47,416 (25)1,116 (30)77,791 (22)
Male, n (% of n1)5,305 (34)2,909 (49)23,366 (47)17,301 (52)29,463 (48)97,730 (52)1,664 (44)177,738 (50)
White Caucasian, n (% of n1)11,698 (76)4,622 (77)33,215 (67)22,710 (69)43,076 (70)130,418 (69)2,575 (68)248,314 (69)
HbA1c, %*7.8 (1.6)8.1 (1.8)9.3 (2.3)7.9 (1.7)8.2 (1.7)8.4 (1.8)7.5 (1.6)8.4 (1.9)
HbA1c, mmol/mol6265786366685868
HbA1c ≥7.5% (58 mmol/mol), n (% of n1)3,890 (44)2,102 (59)19,083 (73)8,150 (46)20,960 (57)65,980 (62)587 (41)118,063 (60)
HbA1c ≥8% (64 mmol/mol), n (% of n1)2,913 (33)1,581 (44)16,871 (64)6,106 (34)15,768 (43)51,841 (49)418 (29)93,499 (48)
Weight, kg*108.1 (25.9)105.1 (25.2)99.8 (26)99.9 (24.3)98 (24.2)98 (24.6)94 (26.1)98.9 (24.9)
BMI, kg/m2*38.1 (8.2)36.2 (7.8)35 (8.3)34.8 (7.8)34.3 (7.6)34.3 (7.7)33.3 (7.9)34.6 (7.8)
Obese, n (% of n1)12,429 (86)4,387 (79)32,472 (71)20,920 (71)39,574 (69)117,232 (68)1,961 (61)222,627 (70)
SBP, mmHg*128 (14)129 (14)131 (16)130 (15)130 (14)132 (15)129 (15)131 (15)
SBP ≥140 mmHg, n (% of n1)2,565 (18)1,098 (20)11,642 (25)6,993 (24)12,446 (22)46,191 (27)703 (22)79,837 (25)
DBP, mmHg*78 (9)79 (9)76 (10)77 (9)78 (9)77 (10)75 (9)77 (9)
Heart rate, bpm*81 (11)80 (12)80 (12)78 (11)79 (11)79 (12)78 (12)79 (12)
LDL, mg/dL*96 (34)79 (9)98 (37)97 (35)98 (35)97 (35)75 (9)97 (35)
HDL, mg/dL*44 (12)43 (12)43 (13)45 (13)44 (12)43 (12)47 (15)43 (12)
Triglycerides, mg/dL150 (109, 200)156 (115, 207)143 (103, 196)139 (100, 190)148 (109, 197)149 (109, 199)135 (97, 185)147 (107, 197)
CVD, n (% of n1)2,134 (14)1,004 (17)11,781 (24)5,894 (18)12,212 (20)41,220 (22)876 (23)75,121 (21)
CKD, n (% of n1)301 (2)128 (2)1,686 (3)836 (3)2,090 (3)6,806 (4)140 (4)11,987 (3)
Cancer, n (% of n1)606 (4)264 (4)2,554 (5)1,350 (4)3,359 (5)9,472 (5)237 (6)17,842 (5)
Depression, n (% of n1)2,979 (19)1,123 (19)7,294 (15)3,710 (11)9,073 (15)23,433 (12)465 (12)48,077 (13)
Charlson Comorbidity Index*1.52 (0.9)1.58 0.0(1)1.71 (1.16)1.48 (0.92)1.63 (1.08)1.63 (1.08)1.69 (1.11)1.62 (1.07)
  • bpm, beats per minute; n1, number of subcohort 1 patients prescribed each drug class as a second ADD; n2, number of n1 patients with ≥1 year follow-up after second ADD initiation.

  • *Mean (SD);

  • †median (interquartile range);

  • ‡mean;

  • §other: amylin, DOPRA, AGI, or MEG;

  • ‖subcohort 1: initiated second ADD and had MET as first-line treatment.